Short answer
Taysha Gene Therapies, Inc. (TSHA) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$42M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$42M
- −97.0% YoY
- EPS (diluted)
- −$0.12
- −50.0% YoY
Source: XBRL data from the Taysha Gene Therapies, Inc. (TSHA) Q1 2026 10-Q on SEC EDGAR. USD.
Taysha Gene Therapies, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0 vs $2.302M YoY, with no product sales
- Net loss $42.4M for three months ended March 31, 2026
- Cash deployment included $3.0M investing outflow for Abeona milestone payment
- REVEAL pivotal dosing expected complete Q2 2026; ASPIRE dosing also expected complete Q2 2026
- PPQ campaign initiated April 2026, completion expected Q4 2026; continued significant operating losses anticipated
Risk Factors
- No risk-factors section provided in the submitted excerpt
- No newly added risk or changed risk disclosed
- No regulatory, legal, operational, competitive, market, or financial risk details available
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Taysha Gene Therapies, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.